Glucocorticoids (GC
Introduction
Glucocorticoids (GC) are involved in many biological processes, including metabolism, development, differentiation, immunity, reproduction and neural activity. The diverse actions of GC have led to their use as therapeutic agents in the treatment of many diseases. GC can act in an anti-proliferative manner in specific cell types, which is the reason why GC are used in immunosuppressive, anti-inflammatory and oncolytic therapy. The effect on lymphoid cells is dramatic and includes the induction of G1 cell cycle arrest and apoptosis. In newly diagnosed acute lymphoblastic leukemia (ALL), prednisone and dexamethasone have significant antileukemic effect in the majority of children. 1 Although GC are the most important drugs used in the treatment of ALL for more than 50 years, the molecular basis of GC sensitivity and resistance remains largely unknown. Understanding of the molecular mechanisms related to GC cytotoxicity is crucial for understanding a major part of treatment success or failure in childhood ALL and is crucial for the exploration of possibilities to modulate GC resistance. This review summarizes the current knowledge on molecular determinants of glucocorticoid sensitivity and resistance in ALL.
apy with prednisone (including one intrathecal dose of methotrexate) was shown to be a strong and independent prognostic factor. [1] [2] [3] Subgroups with a poor prognosis like infants, T-ALL patients and patients with a Philadelphia chromosome-positive ALL, more often show a poor clinical response to prednisone. 2, 4, 5 In vitro resistance to glucocorticoids at initial diagnosis is also related to an unfavorable eventfree survival in childhood ALL. [6] [7] [8] [9] Leukemic cells from the risk groups associated with a poor prognosis (T-ALL, proB-ALL, infant ALL) are relatively in vitro resistant to prednisolone. 10 Leukemic cells from adults with ALL, who have an unfavorable outcome as compared with children, are also more resistant to GC in vitro. 11, 12 Leukemic cells of patients with relapsed ALL are 300-fold more in vitro resistant to prednisolone than the cells taken at diagnosis: in paired initial/relapse samples resistance to GC increased in the majority of patients at the time of relapse compared to initial diagnosis. 13 
The glucocorticoid receptor gene and activation by glucocorticoids
The glucocorticoid receptor gene (GR) is located on chromosome 5 (5q31) and consists of nine exons encoding for three characteristic domains of the protein (Figure 1) . 14 The N-terminal region contains a transactivation domain (AF-1) that is involved in transcriptional activation of target genes. 15 An internal DNA binding domain consisting of two highly conserved 'zinc fingers' is crucial for the binding to the glucocorticoid response elements (GRE) sequence. This domain contains a nuclear localization signal (NLS1). The first zinc finger (exon 3) encodes for domains necessary for binding NF-B and AP-1 16 and is therefore important for the transrepression mode of the receptor. The second zinc finger domain (exon 4) encodes for receptor dimerization and GRE-mediated transactivation. [17] [18] [19] [20] The C-terminal part of the protein contains the ligand binding domain that also binds heat-shock proteins (hsp) and is involved in receptor dimerization. This domain contains a second nuclear localization signal (NLS2) and transcription activation (AF-2) site. 15, 19 The two transactivation domains (AF-1 and AF-2) interact with other nuclear proteins such as CBP (CREB binding protein) and P300 that are important for stabilization and activation of the transcription initiation complex in the promotors of glucocorticoid-responsive genes. 21 GC enter the cell by passive diffusion and bind to the GR which is located in the cytoplasm as a homodimer (Figure 2) .
The GR belongs to the nuclear hormone receptor superfamily, and is highly homologous to the mineralocorticoid, progesterone and androgen receptor. Binding of GC to the GR triggers the dissociation of proteins bound to the receptor such as hsp and BAG-1. 22 This discloses and activates the nuclear localization signal (NLS) domains of the receptor. The GC-
Figure 1
Schematic overview of the GR gene. The GR gene, localized on chromosome 5, consists of nine coding exons. The functional parts of the receptor are indicated.
Figure 2
Model of GC-induced apoptosis in leukemic cells. Glucocorticoids (GC) enter the cell by passive transport, and bind to the glucocorticoid receptor (GR). The unbound GR forms heterocomplexes consisting of heat-shock chaperone molecules hsp90 and 70, co-chaperone molecules hsp40, Hop (p60), p23 and immunophillins FKBp52 and CyP40, required for optimal configuration of the GR to be able to bind GC. As a homodimer the GC-GR complex translocates to the nucleus. There it interacts with either a GRE (consensus sequence (GGT ACA NNN TGT TCT) of a target gene (transactivation), or it interacts with other transcription factors such as AP-1 and NF-B (transrepression). Both processes may finally result in the induction of cell death (apoptosis). NF-B is kept in the cytoplasm in a complex with IB␣. Upon dissociation it can translocate to the nucleus.
GR complex then translocates to the nucleus as a homodimer, where it can interact with GREs (consensus sequence GGT ACA NNN TGT TCT 23 ). These are located in promotor regions of GC-responsive genes, leading to transcriptional activation or inactivation of these genes (the latter hardly ever occurs). 24 The GC-GR complex can also directly interact with transcription factors like activating protein-1 (AP-1) or nuclear factor B (NF-B), by forming transrepression complexes. The formation of these complexes represses the transcriptional activity of both the GR, AP-1 and NF-B. 25 Both transactivation (via GRE-binding) and transrepression (via interaction with AP-1 or NF-B) processes can induce apoptosis of GC-sensitive cells, but it is yet unknown if one or both are important in ALL. 16, [26] [27] [28] [29] [30] Molecular mechanisms of sensitivity and resistance in leukemic cells
Number of glucocorticoid receptors
The relationship between the number of GR per cell and the response to GC in patients with ALL has been the subject of many studies, as reviewed earlier. 31 Most authors report a significant correlation between low numbers of receptor per cell and a higher rate of induction failure or relapse. However, a high receptor number does not necessarily predict a good response to a GC-containing regimen. All studies about GR numbers used dexamethasone binding assays in which only functional receptors are measured (ie probably the ␣-and the ␥-isoform -see below).
In contrast to basal expression levels of the receptor, upregulation of the number of GR upon GC exposure may be more important for GC-induced apoptosis. In non-lymphoid cell lines and in peripheral blood mononuclear cells of children with auto-immune disorders, with no apoptotic response upon GC exposure, a decrease in GR mRNA expression and receptor number was observed after exposure to GC. [32] [33] [34] [35] [36] [37] Contrary to the down-regulation in those non-lymphoid cell lines, up-regulation of the GR upon GC exposure is reported in leukemic and lymphoid cell lines. In the leukemic T cell line, CCRF-CEM, an up-regulation of GR mRNA was shown in the first few hours after exposure to GC. 38 Ramdas et al 39 showed that the basal level of GR expression is inadequate to mediate glucocorticoid-induced apoptosis in a leukemic human T cell line 6TG1.1. An increase in GR number by autoregulation is required to induce apoptosis in these cells. Recently, Breslin et al 40 studied the hypothesis that activation of different promotors of the GR gene may regulate the expression of GR under the influence of GC in different tissues. Exon 1A3 mRNA (one of at least five transcripts from three different promoters) is expressed most abundantly in hematological cancer cell lines that are sensitive to GCinduced apoptosis. Furthermore, GC exposure causes upregulation of exon 1A3-containing GR transcripts in (hematological) CEM-C7 cells.
No data exist proving the hypothesis that leukemic cells that are sensitive to GC are able to up-regulate their receptor number more pronouncedly than resistant leukemic cells.
Membrane bound receptor
Whereas the GR is generally described as a cytosolic receptor, Gametchu et al 41 described a membrane-bound variant (mGR). The expression of the mGR is reported to be cell cycle regulated in the CCRF-CEM cell line. The highest expression is found during the late S-G 2 /M phase when the cells are most sensitive to the apoptotic effect of GC. The mGR expression varied among leukemic patients, whereas no mGR was found in the membrane of lymphocytes of healthy individuals, the latter being highly resistant to GC. 41, 42 In a pilot study no correlation was found between the expression of mGR and in vitro sensitivity to GC in childhood ALL samples (Gametchu, personal communication).
Polymorphisms/somatic mutations of the glucocorticoid receptor gene
A number of endocrinological glucocorticoid resistance syndromes have been described that are associated with genetic mutations in the GR. [43] [44] [45] [46] [47] (A genetic mutation is defined as an inheritable germline mutation present in a limited number of individuals (most commonly within a family) and associated with a higher risk to develop a malignancy (eg Li Fraumeni syndrome). A polymorphism is defined as an inheritable genetic germline variant of a single locus (most frequently a single nucleotide variation) that is present in at least 1% of the population. The opposite of polymorphisms are somatic mutations that are associated with a specific type of disease, and thereby restricted to the malignant cells only.) These mutations result in a lower number of functional receptors and interfere with GC binding or transactivational capacity. Besides genetic mutations, several polymorphisms have been described. Although most polymorphisms do not effect receptor function, 48 ,49 one polymorphism has been described which is associated with increased sensitivity to GC. This N363S polymorphism is present in 3-6% of the population. [49] [50] [51] Table 1 summarizes the literature references on polymorphisms and mutations in the GR as found in healthy individuals, a patient with childhood ALL and patients with a glucocorticoid resistance syndrome.
The role of polymorphisms or somatic mutations in the GR in relation to GC cytotoxicity in childhood leukemia is largely unknown. Hillman et al 52 showed that the GC-resistant CCRF-CEM cell line contains one GR allele with the L753F mutation. Analysis of the original biopsy material also revealed the same mutation, but in a substantially lower frequency than expected, concordant with the hypothesis that this mutation was only limited to a leukemic subclone. Table 1 Polymorphisms and mutations in the glucocorticoid receptor gene described in healthy individuals, a patient with childhood ALL and patients with a glucocorticoid resistance syndrome The different mutations can cause a decreased sensitivity to GC in various ways. Decreased sensitivity to GC may be related to the location of the mutation (N-terminal, DNA-binding region or ligand-binding region) or to the preferential degradation of mutated GR. The GR transcript can be truncated by a mutation, which introduces a premature stop codon, resulting in loss of mRNA expression and loss of GR number and associated with a decreased GC sensitivity. 43, 52 Other mutations may interfere with correct splicing of the pre-mRNA transcript. Karl et al 43 showed that a four-basepair deletion on the boundary of exon 6 resulted in the absence of transcripts of that allele, so GR is only encoded by one wild type allele. The relevance of polymorphisms and genetic or somatic mutations in the GR gene for GC sensitivity and prognosis in childhood leukemia is the subject of ongoing studies in our laboratory 53 and of others. If these genetic aberrations are important for the cellular response to GC, the presence of these polymorphisms/mutations can be used to identify patients at risk for a poor response to GC treatment. In addition, patients with a polymorphism that is associated with increased GC sensitivity like the N363S polymorphism may benefit from GC in their treatment. However, these patients may also suffer from severe side-effects, such as Cushing syndrome, overweight, depression and avascular necrosis of bone. These patients may still have an excellent prognosis when treated with a lower dosage of GC.
Splice variants of the glucocorticoid receptor
Five different splice variants of the GR gene have been described, formed by alternative splicing, ie the ␣, ␤, ␥, GR-P and GR-A isoform (see Figure 3) .
(1) The ␣ isoform is the functional receptor and is encoded for by exon 2 to 9␣. 54 It is located in the cytoplasm in the absence of GC, but migrates to the nucleus upon GC binding. 55 The only study of the relationship between splice variants and GC sensitivity in leukemic patients was done by Longui et al 56 They described a reduced GR␣ expression in the leukemic blasts of 13 ALL patients in comparison with EBV transformed lymphocytes of nine normal controls. The GR␣ expression was lowest in T-ALL samples and no concomitant decrease in GR␤ expression in the leukemic cells of these patients was observed. The authors suggest that decreased GR␣ expression levels may explain the lower GC sensitivity in T-ALL patients as compared to pre B-ALL. However, the proof for the relevance
Figure 3
The glucocorticoid receptor gene and five different splice variants.
of the alpha splice variant is indirect as there was no in vitro or in vivo assessment of GC sensitivity and patient number is very small. (2) The ␤ isoform is the result of alternative splicing of exon 9␤ instead of 9␣, resulting in 15 unique C-terminal amino acids. As a consequence, GR␤ cannot bind GC. 54 At mRNA level, GR␤ expression is 0.2-1% of the total GR expression. 57, 58 Strikingly, at protein level, the data are controversial and vary from levels comparable to mRNA levels 59, 60 to five-fold higher expression levels compared with GR␣. 61 The reason for these conflicting data might be lack of specificity of the antibodies used in these studies.
The ␤ isoform might have a dominant negative effect over the ␣ isoform. Carlstedt-Duke 62 and Vottero and Chrousos 63 reviewed the controversial data on this hypothesis. In GC-resistant asthma patients, Leung et al 64 found a relatively higher expression of GR␤ in peripheral blood mononuclear cells as compared to GC-sensitive asthma patients, but Gagliardo et al could not confirm this. 65 Transfection studies in cell lines are also inconclusive. Some transfection studies showed a negative effect of GR␤ over GR␣, 66, 67 whereas others did not. 60, 68, 69 As the expression level of the beta isoform is very low compared to the alpha isoform, the relevance of the beta expression or resistance in childhood leukemia is unlikely. (3) The ␥ isoform has only recently been described. 70 In this splice variant exon 4 is alternatively spliced to exon 3 thereby including three basepairs of the intron region resulting in an additional arginine residue. This isoform is expressed at 3.8-8.7% of total GR mRNA in different human tissues but it is unknown whether this variant is a separate splice variant or part of the ␣, ␤ and GR-P isoforms. 70 , 71 Ray et al 72 reported that the biological activity of the ␥ isoform is reduced to 50% of the wild-type receptor. Gerdes et al 71 reported preliminary results showing a possible role for the ␥ isoform in poor prednisone response in childhood ALL. (4) The GR-P isoform is encoded by exons 2-7 plus several basepairs from the subsequent intron region. 73 As a consequence, this isoform lacks the ligand binding domain and therefore cannot bind GC. The GR-P transcripts account for up to 10-20% of total GR mRNA, but has been reported to be up-regulated in a small group of hematological malignancies (ALL, non-Hodgkin's lymphoma and multiple myeloma, up to 54% of total GR mRNA). 57, [74] [75] [76] In a study of de Lange et al, 77 transfection of GR-P receptor increased the activity of the GR␣ receptor. In the same study no relationship was found between sensitivity to GC and the ratios of the GR␣, GR␤ and GR-P isoforms in a group of multiple myeloma patients. ( 5) The fifth variant described, the GR-A variant, has an excision of exons 5, 6 and 7, resulting in the in frame juxtaposition of exon 8 to 4. No further information is known about the expression levels and function of this variant. 73 Studying the relevance of the alpha, beta and hGR-P splice variants for GC sensitivity in childhood ALL, preliminary data from our laboratory did not show a relation between mRNA levels of the three splice variants and in vivo or in vitro sensitivity to GC. Further work is needed to define the importance of the different splice variants in relation to GC sensitivity in ALL and to delineate the mechanisms of GR mRNA splicing regulation.
Phosphorylation of the GR
Phosphorylation of receptors is a general regulation mechanism in cells. Phosphorylation of the GR modulates the GR function as reviewed by Bodwell et al. 78 The phosphorylation rate is maximal in the S-phase and enhances the transactivating and transrepressing activities of the GR. Furthermore, the GR is destabilized by phosphorylation, resulting in a shorter half-life of the protein. The clinical relevance of phosphorylation of the GR is unknown.
Multidrug resistance and GC sensitivity
P-glycoprotein (P-gp) is a drug-efflux pump responsible for multidrug resistance (MDR) and encoded for by the mdr-1 gene. In a murine thymoma cell line it was shown that increased resistance to dexamethasone was linked to an increased expression of the mdr1 gene of P-gp. Verapamil, able to restore intracellular drug concentrations by blocking the drug-efflux pump, was able to increase the intracellular level of dexamethasone. 79, 80 However, contrary to these cell line studies, in a report on leukemic cells of 112 children with ALL no correlation between GC resistance in vitro and the expression or function of P-gp activity was found. 81 Furthermore, functional P-gp activity was not related to in vivo prednisone response in a group of 90 ALL patients. 82 In addition, GC resistance was not associated with an increased expression of other multi-drug resistance-related proteins such as major vault protein/lung resistance protein (MVP/LRP) and multidrug resistance-associated protein (MRP-1). 81 
Glutathione and glutathione S-transferase
Increased glutathione (GSH) levels and glutathione S-transferase overexpression contribute to resistance to various cytostatic drugs. Maung et al 83 found in their study of 21 newly diagnosed patients a positive correlation between GSH level and prednisolone resistance. However, in a recent report concerning 62 newly diagnosed children with ALL, this relationship was not confirmed. 84 In addition, the expression levels of GST (␣, and -class) were not related to in vitro prednisolone sensitivity in childhood ALL. 85 Anderer et al 86 reported the implication of polymorphisms in the GST genes for GC sensitivity in childhood ALL. In a case-control study of 45 in vivo poor responders and 90 good responders there was a reduced risk of prednisone poor response in patients with a homozygous deletion of GSTT1 (null genotype), although this difference was not statistically significant (P = 0.071).
Protein interaction with the GR in the cytoplasm
The unstimulated GR is sequestered within the cytoplasm where it can bind into heterocomplexes consisting of heatshock chaperone molecules hsp90 and 70, co-chaperone molecules hsp40, Hop (p60), p23 and immunophillins FKBP52 and CyP40. This heterocomplex is required for optimal configuration of the GR to be able to bind GC. 87 In a recent study, only Hsp 90 and Hsp 70 were found to be required and were sufficient for GC binding to its receptor. 88 A second function of the heat-shock chaperone molecules is the formation of a heterocomplex with GR, which induces a conformational change in the ligand-binding domain of the 21 receptor, facilitating nuclear transport of the receptor. 22 Kojika et al 89 reported the adverse effect of abnormal expression of hsp90 and low expression of hsp70 on sensitivity to GC in 2 human leukemic cell lines.
Another co-chaperone molecule BAG-1 (also named RAP46) has been found to bind to many different proteins including hsp70. This molecule may inhibit hsp70 function and GR-heterocomplex formation thereby interfering with GC binding to the GR. 90, 91 It is tempting to speculate that overexpression of BAG-1 may result in cellular resistance to GC, and indeed, cell line studies have demonstrated that BAG-1 overexpression resulted in cellular resistance against dexamethasone-induced apoptosis. 91 
Glucocorticoids and transcription factors
Besides binding to the GRE, the GC-GR complex is thought to recruit NF-B and AP-1 into a transrepression complex. This complex abrogates the transcriptional activation of GR, NF-B and AP-1 responsive genes (transrepression). Besides physical interaction and inactivation of NF-B by the GC-GR complex, 92 NF-B is also inactivated by a second mechanism. Since IB␣ is a GR-responsive gene, [93] [94] [95] induction of GR leads to higher levels of IB␣ which decreases the level of nuclear NF-B. Enhanced expression of IB␣ may thereby stimulate GC-induced apoptosis. 95, 96 Contrary to this hypothesis are the results from Heck et al 97 who conclude by dimerization-defective GR mutant studies that IB␣ synthesis is neither required nor sufficient for the hormone-mediated down-regulation of NF-B activity. 97 The only study using leukemic blasts from children with ALL did not find a difference in NF-B level in a group of 42 good and poor in vivo responders to GC. 98 The second transcription factor interacting with GR is AP-1, a heterodimer of Fos and Jun proteins. Since AP-1 target genes are involved in cell proliferation, a reduction of functional AP-1 levels may therefore facilitate apoptosis. However, Bailey et al 99 did not find a relationship between levels of AP-1 and in vitro prednisolone resistance in ALL and chronic lymphoid leukemia blasts, nor between prednisolone-induced changes in AP-1 binding activity and in vitro GC resistance.
It is not known whether GR-GRE binding, GR interactions with transcription factors or both are of importance for GCinduced apoptosis in ALL. Favoring the importance of GR-GRE binding are the results from a study by Reichardt et al 27 An A458T point mutation was introduced in the DNA-binding region of mouse GR, thereby abolishing GRE binding. T lymphocytes of these mutant mice were refractory to dexamethasone-induced apoptosis, whereas wild-type T lymphocytes were highly sensitive to dexamethasone-induced apoptosis.
Genes regulated by GC
Many genes have been proposed to be regulated by GC. 29, 100 GC induce G0/G1 arrest of proliferating cells. This suggests that GC reduce the expression of genes related to cell growth and cell viability. An important gene is c-myc, a known target gene of NF-B. Thompson et al concluded in their studies that negative regulation of c-myc expression is a significant step in the initial pathway leading to apoptosis in the CEM cell line. [101] [102] [103] Non-obese diabetic (NOD) mice with T lymphocytes that are resistant to GC-inducible apoptosis show no reduced c-myc levels after GC. 104 On the contrary, Lö ffler et Leukemia al 105 reported that c-myc down-regulation may not be critical for induction of cell death by GC since transfection of c-myc into the human T cell leukemia CEM cell line increased the sensitivity to GC-induced cell death. One of the reasons for these conflicting results may be that increased c-myc expression sensitizes the CEM cell line to apoptosis in a similar way as shown by Evan et al, 106 ie an enhancement of apoptosis by enforced c-myc expression following growth-factor deprivation which was observed in the absence of GC treatment.
Another important target gene, known to be up-regulated in a leukemic cell line but down-regulated in cells not undergoing apoptosis after GC exposure is the GR gene itself. 29, [32] [33] [34] 36, 39 The relationship between the potency to upregulate the GR number and sensitivity to GC in ALL is currently the subject of study in different laboratories.
Using gene chip arrays, many genes have been found to be regulated under the influence of GC. A notable cluster of the repressed genes seemed to be of importance for the processes of transcription, mRNA splicing and protein synthesis. It remains to be shown whether GC trigger one specific apoptotic pathway or that a more general suppression of macromolecule synthesis is the cause of apoptosis. 107 
Apoptosis pathway
Glucocorticoids induce apoptosis in leukemic cells. Both transactivation of GRE-containing genes and transrepression of genes via NF-B and AP-1 interactions are probably essential. 16, [26] [27] [28] 30 In rat thymocytes it was shown that glucocorticoid-induced apoptosis depends on protein synthesis and de novo gene expression. 108 There are two major apoptosis pathways: the first starting with a disruption of the mitochondrial membrane potential and cytochrome c and SMAC release after which caspase 9 is activated. This pathway seems to be important for GC-induced apoptosis. 109, 110 The second apoptosis pathway, induced by membrane death receptors as reviewed by Ashkenzi and Dixit, 111 is not critically involved in the apoptotic response to GC. 29 Brady et al 112 showed that the apoptosis pathway induced by GC is p53 independent.
An important protein studied in relation to GC-induced cell death is the anti-apoptotic protein Bcl-2. Hartmann et al 113 reported that Bcl-2 protects cells against GC-induced apoptosis in the human T-ALL cell line (CCRF-CEM) for up to 48 h. However, when cultured for another 24 h, these cells undergo massive apoptosis. Bcl-2 did not affect GC-mediated growth arrest, thereby separating the anti-proliferative effect of GC from the apoptosis-inducing. 113 This was confirmed in other studies, as GC in the presence of high levels of Bcl-2 only has an anti-proliferative effect but not an apoptotic effect, while in the presence of low Bcl-2 expression, GC induced apoptosis. [114] [115] [116] In different studies in children with ALL, expression of Bcl-2 or Bcl-2 family members could not be related to in vitro or in vivo GC resistance. [117] [118] [119] Contrary to the hypothesis that the anti-apoptotic protein Bcl-2 is related to resistance to GC-induced apoptosis are the results of a study of 110 patients treated according to the German BFM protocols. Good responders to initial prednisone therapy had higher Bcl-2 expression levels than poor responders. The authors speculate that this high Bcl-2 expression might be due to up-regulation by cytokines, which may also be important for in vivo tumor cell survival. 82 Bcl-2 is a member of a larger Bcl-2 family, consisting of both pro-as well as anti-apoptotic proteins. It could be that not the absolute expression of Bcl-Leukemia 2, but the ratio of all family members are the most important in determining sensitivity to GC treatment in ALL. However Salomons et al 117 did not find a relationship between the Bax:Bcl-2 ratio and the response to 7 days monotherapy of prednisone in a group of 76 patients.
The final activation of caspases seems to be a downstream effector event during apoptosis, but the trigger for this pathway remains unknown. Kofler suggests that the continuous repression of metabolic pathways by GR up-regulation contributes to cell cycle arrest, ultimately leading to apoptosis. Particularly critical in this context might be the down-regulation of lactate dehydrogenase, an enzyme controlling glycolysis in cells. 29, 38 The suggestion that metabolic events have to take place before the induction of apoptosis may be in accordance with our own unpublished in vitro observations that induction of apoptosis in ALL cells derived from patients is a late event starting only after 24 h from the start of exposure to GC.
Perspectives
In vivo and in vitro sensitivity to GC are associated with prognosis in childhood ALL. This review has summarized the knowledge on genes and proteins that regulate GC sensitivity. Future studies should focus on polymorphisms, splice variants and regulation of the GR, on transcription factors activated or repressed by GC and on downstream molecules that control the apoptotic cascade. Based upon knowledge derived from these studies, strategies to modulate GC resistance in ALL can be developed.
